AKT1 and neoplasm: reported that the application of the DKK1 inhibitor WAY-262611 can suppress the PI3K/AKT and Wnt/β-catenin signaling pathways through the modulation of Glycogen synthase kinase 3 beta (GSK-3β) activity, thereby markedly augmenting the anti-tumor effectiveness of sorafenib (15).